REFERENCES

- 1 Moroni E, Dell'Era P, Rusnati M, Presta M. Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors. *J Hematother Stem Cell Res* 2002; **11**: 19–32.
- 2 Ghosh AK, Kay NE. Critical signal transduction pathways in CLL. *Adv Exp Med Biol* 2013; **792**: 215–239.
- 3 Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. *Nat Rev Cancer* 2010; **10**: 116–129.
- 4 Johnston CL, Cox HC, Gomm JJ, Coombes RC. Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus. *J Biol Chem* 1995; **270**: 30643–30650.
- 5 Mohammadi M, Dikic I, Sorokin A, Burgess WH, Jaye M, Schlessinger J. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. *Mol Cell Biol* 1996; **16**: 977–989.
- 6 Ghosh AK, Secreto C, Boysen J, Sassoon T, Shanafelt TD, Mukhopadhyay D *et al*. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. *Blood* 2011; **117**: 1928–1937.
- 7 Boysen J, Sinha S, Price-Troska T, Warner SL, Bearss DJ, Viswanatha D *et al*. The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: implications for therapy in p53-defective CLL patients. *Leukemia* 2014; **28**: 451–455.
- 8 Brand TM, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N *et al*. AXL mediates resistance to cetuximab therapy. *Cancer Res* 2014; **74**: 5152–5164.
- 9 Sinha S, Boysen J, Nelson M, Secreto C, Warner SL, Bearss DJ *et al*. Targeted Axl inhibition primes chronic lymphocytic leukemia B cells to apoptosis and shows synergistic/additive effects in combination with BTK inhibitors. *Clin Cancer Res* 2015; **21**: 2115–2126.
- 10 Chase A, Grand FH, Cross NC. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. *Blood* 2007; **110**: 3729–3734.
- 11 Korah RM, Sysounthone V, Golowa Y, Wieder R. Basic fibroblast growth factor confers a less malignant phenotype in MDA-MB-231 human breast cancer cells. *Cancer Res* 2000; **60**: 733–740.
- 12 Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W *et al*. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. *Cancer Res* 2010; **70**: 1544–1554.
- 13 L'Hote CG, Knowles MA. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. *Exp Cell Res* 2005; **304**: 417–431.
- 14 Azab AK, Azab F, Quang P, Maiso P, Sacco A, Ngo HT *et al*. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. *Clin Cancer Res* 2011; **17**: 4389–4399.
- 15 Hynes NE, Ingham PW, Lim WA, Marshall CJ, Massague J, Pawson T. Signalling change: signal transduction through the decades. *Nat Rev Mol Cell Biol* 2013; **14**: 393–398.

Supplementary Information accompanies this paper on the Leukemia website (<http://www.nature.com/leu>)

OPEN

Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia

Leukemia (2016) **30**, 1436–1440; doi:10.1038/leu.2015.331

IKZF1 (*Ikaros*) encodes a DNA-binding protein that acts as a master regulatory of hematopoiesis and a tumor suppressor in acute lymphoblastic leukemia (ALL).^{1–4} The deletion and/or mutation of *Ikaros* is associated with the development of B-cell acute lymphoblastic leukemia (B-ALL) with poor outcome.^{5–11} *Ikaros* directly associates with components of the histone deacetylase complex (NuRD), HDAC1, HDAC2 and Mi-2.^{12–14} Although *Ikaros* is hypothesized to regulate the transcription of target genes by recruiting the NuRD complex, the mechanism of *Ikaros*-mediated transcriptional regulation in leukemia is still unknown. Here we use a systems biology approach to determine the mechanism through which *Ikaros* and HDAC1 regulate gene expression in human B-ALL.

To study the role of *Ikaros* and *Ikaros*–HDAC1 complexes in ALL, we determined the genome-wide occupancy of *Ikaros* and HDAC1 using chromatin immunoprecipitation followed by deep sequencing (ChIP-Seq) in human B-ALL cells (Nalm6 cell line). We identified 12 464 distinct binding sites for *Ikaros* and 9971 for HDAC1, and these were associated with 6722 and 6182 target genes, respectively (Figure 1a). Of these, 12% of the *Ikaros*-binding sites overlapped by at least 1 bp with 14.6% of the HDAC1-binding sites. The overlapping binding sites correlated with 934 gene targets (Figure 1a). ChIP-Seq data for *Ikaros* and HDAC1 were validated by quantitative chromatin immunoprecipitation (qChIP) analysis of the high- and low-rank ChIP-Seq peak values (Supplementary Figures S1 and S2). The peak distributions of *Ikaros* and of HDAC1 relative to target genes revealed that the

binding of both proteins is highly enriched within ± 3 kb from transcriptional start sites (Figure 1b).

We analyzed the effect of *Ikaros* and HDAC1 DNA binding on the surrounding chromatin. First, the genome-wide distribution of histone H3 trimethylation at lysine 4 (H3K4me³), lysine 27 (H3K27me³), lysine 36 (H3K36me³), or lysine 9 (H3K9me³), or acetylated at lysine 9 (H3K9ac) was determined by ChIP-Seq experiments in Nalm6 cells. ChIP-Seq data for histone modifications were validated by qChIP analysis of the high- and low-rank ChIP-Seq peak values (Supplementary Figures S3–S7). Next, we analyzed the distribution of chromatin modifications relative to (1) *Ikaros* peaks; (2) *Ikaros*–HDAC1 overlapped peaks; and (3) HDAC1 peaks. Most of the *Ikaros* and HDAC1 binding occurs within the promoters of target genes (Figure 1b). Thus, we compared the epigenetic changes that we observed in chromatin surrounding *Ikaros*, *Ikaros*–HDAC1 and HDAC1 peaks (Figures 1c–e), which are located within the promoter region, to epigenetic markers present in chromatin surrounding promoters across the genome, regardless of *Ikaros* and/or HDAC1 occupancy (Figure 1f).

We found that unique epigenetic changes are associated with *Ikaros*, *Ikaros*–HDAC1 and HDAC1 peaks. *Ikaros* peaks are associated with the presence of H3K4me³, H3K9me³ and H3K9ac histone modifications (Figure 1c). *Ikaros*–HDAC1 overlapped peaks correlated with a different chromatin environment that is characterized by the very strong presence of H3K4me³ and H3K27me³, moderate H3K9me³ and virtually absent H3K9ac (Figure 1d). HDAC1 peaks were also associated with the very strong presence of H3K27me³ and H3K4me³, and virtually absent H3K9ac. However, H3K9me³ was reduced as compared with *Ikaros* or *Ikaros*–HDAC1 peaks (Figure 1e).

Figure 1. Genome-wide mapping of Ikaros and HDAC1 binding in B-ALL cells. **(a)** Ikaros and HDAC1 target genes identified by ChIP-Seq analysis of Nalm6 B-ALL cells. The overlapping gene targets have Ikaros and HDAC1 peaks overlapped by at least 1 bp. **(b)** The distribution of Ikaros and HDAC1 peaks around the transcriptional start sites (TSS). Peak numbers were normalized by treating the maximum possible peak number at a location as 100. **(c–f)** Specific epigenetic changes associated with Ikaros and HDAC1 occupancy. The distribution of histone modifications relative to the center of **(c)** the Ikaros peak; **(d)** the Ikaros peak in Ikaros (IK)-HDAC1 overlapped peaks; **(e)** the HDAC1 peak; **(f)** all TSS, genome wide. Graphed is the frequency of each particular epigenetic modifications per 100 Ikaros, or 100 Ikaros-HDAC1 peaks, over a 1 kb span. **(g)** Association of H3K27me³ with IK and HDAC1 occupancy, genome wide (left), or within the promoter region (right). Graphed are the number of H3K27me³ peaks located within 1 kb of IK, HDAC1, or IK-HDAC1 peaks, or outside of these regions (non-IK and non-HDAC1). **(h)** Effect of pan-HDAC inhibitor (TSA) on H3K27me³ level. Western blot of H3K27me³ in untreated Nalm6 cells and following TSA treatment at specific days are shown. The total level of histone H3 was used for normalization (bottom). WT, wild type.

These results indicate that the binding of Ikaros, Ikaros-HDAC1 or HDAC1 is each associated with a distinct characteristic chromatin change that likely affects the expression of target genes. The specific distribution of histone modifications around Ikaros, Ikaros-HDAC1 or HDAC1 peaks were similar, regardless of whether these peaks were localized within promoter regions or other regions across the genome (Supplementary Figures S8–S10). Most of the specific epigenetic changes occur within 1 kb of the center of the Ikaros, Ikaros-HDAC1 or HDAC1 peaks. This suggests that binding of these proteins has a direct effect on chromatin remodeling and the observed epigenetic changes.

Our analysis demonstrates a strong association between HDAC1 occupancy and H3K27me³ (Supplementary Table S1). This is particularly pronounced at promoter regions—85% of all promoters with H3K27me³ showed HDAC1 binding (Figure 1g). This suggests that HDAC1 occupancy is the major determinant of the H3K27me³ marker. Further analysis demonstrates Ikaros-HDAC1 occupancy at 21% of all promoters with H3K27me³ in leukemia cells (Figure 1g). This suggests that Ikaros binding to promoters of its target genes can result in H3K27me³ via recruitment of HDAC1. These results show the importance of Ikaros' recruitment of HDAC1 in determining the global epigenetic signature in leukemia. We tested whether histone deacetylase activity is required for the formation of H3K27me³ in Nalm6 cells. Treatment of Nalm6 cells with the histone deacetylase inhibitor trichostatin resulted in strong reduction of H3K27me³ by western blot (Figure 1h), suggesting that histone deacetylase activity is essential for the presence of H3K27me³. These results demonstrate an essential role for histone deacetylase in the formation of H3K27me³ in B-ALL.

ChIP-Seq analysis of the epigenetic signature around Ikaros occupancy led to the hypothesis that DNA binding of Ikaros or Ikaros-HDAC1 complexes alters the transcription of their respective target genes by induction of distinct epigenetic changes. To test this hypothesis, we analyzed the effect of increased Ikaros expression on chromatin remodeling at promoters of genes that are regulated by Ikaros-only or by Ikaros-HDAC1 complexes. Recently, we reported that Ikaros represses the transcription of a large number of genes that promote cell cycle progression in leukemia.¹⁵ The epigenetic signatures at promoters of the cell cycle-promoting genes *CDC7* and *ANAPC7* (Ikaros-only targets), and *CDC2* and *ANAPC1* (Ikaros-HDAC1 targets) were compared in Nalm6 cells transduced with Ikaros or empty vector (control) using serial qChIP assays. Results showed that increased Ikaros expression is associated with unchanged H3K27me³, increased H3K9me³ and decreased H3K9ac in regulatory elements of the Ikaros-only targets, *CDC7* and *ANAPC7* (Figure 2a, Supplementary Figure S11a, red vs black lines). In contrast, in regulatory elements of the Ikaros-HDAC1 target genes *CDC2* and *ANAPC1*, increased Ikaros expression is associated with increased H3K27me³, unchanged H3K9me³ and decreased H3K9ac (Figure 2b, Supplementary Figure S11b, red vs black lines). These data identify specific epigenetic signatures induced by binding of Ikaros-only and Ikaros-HDAC1 complexes to promoters of Ikaros target genes in B-ALL.

Next, we studied how Ikaros loss-of-function or gain-of-function affects the transcriptional regulation and epigenetic signature of Ikaros target genes in primary high-risk B-ALL cells. In high-risk B-ALL, Ikaros function as a transcriptional regulator is severely impaired due to the deletion of one Ikaros allele and/or functional inactivation of Ikaros protein by Casein Kinase II (CK2) phosphorylation.¹⁵ Inhibition of CK2 has been shown to restore Ikaros activity as transcriptional regulator, resulting in transcriptional repression of Ikaros target genes that promote cell cycle progression.¹⁵ We analyzed the epigenetic signature at promoters of Ikaros and Ikaros-HDAC1

Figure 2. Ikaros-mediated chromatin changes in promoter regions of Ikaros target genes. **(a, b)** Epigenetic signature at promoters of Ikaros target genes following overexpression of Ikaros in Nalm6 cells (red line) or in control Nalm6 cells (black line). The binding of Ikaros and HDAC1, and the histone modification markers, H3K27me³, H3K9me³ and H3K9ac were detected by serial qChIP assays in a representative **(a)** Ikaros-only target gene (*CDC7*) and **(b)** IK-HDAC1 target gene (*CDC2*) in Nalm6 B-ALL cells. **(c, d)** Epigenetic signature at promoters of Ikaros target genes in primary high-risk B-ALL cells that carry deletion of one Ikaros allele (patient 1; black line) and following treatment with the CK2 inhibitor, CX-4945 (red line). The binding of Ikaros, HDAC1 and histone modification markers were detected by serial qChIP assays in the representative **(c)** Ikaros-only target gene (*CDC7*) and **(d)** IK-HDAC1 target gene (*CDC2*) in primary cells from patient 1. Patient characteristics are shown in Supplementary Table S2. Graphed data are means $\pm$ s.d. of data obtained using five primer pairs that span the transcription start site (TSS) of indicated genes. In addition to the presented data, the serial qChIP assays for H3K4me³ did not show any changes following treatment with CX-4945 (data not shown). **(e)** Model of proposed epigenetic mechanisms for Ikaros- and IK-HDAC1-mediated regulation of gene expression.

target genes in primary high-risk B-ALL (with loss of Ikaros function), and in primary high-risk B-ALL cells following treatment with CK2 inhibitors (with restored Ikaros function). In high-risk B-ALL, Ikaros DNA binding to the promoters of its target genes is impaired (Figures 2c and d, Supplementary Figures S12 and S13 black lines). Inhibition of CK2 with a specific CK2 inhibitor, CX-4945, restored Ikaros DNA binding to promoters and induced an epigenetic signature with high-level H3K9me³, reduced H3K9ac and the absence of H3K27me³ at the Ikaros-only target gene, *CDC7* (Figure 2c, Supplementary Figure S12a, red vs black lines). However, for the Ikaros-HDAC1 target, *CDC2*, restoration of Ikaros binding following CK2 inhibition results in a high level of H3K27me³, the loss of H3K9ac and largely unchanged H3K9me³ (Figure 2d, Supplementary Figure S12b, red vs black lines). Results obtained following the restoration of Ikaros function demonstrate that treatment of high-risk B-ALL cells with the CK2 inhibitor CX-4945 results in epigenetic changes that are remarkably similar to those found with increased Ikaros expression in Nalm6 (Figures 2c and d and Supplementary Figures S12 and S13c and d as compared with Figures 2a and b).

The distinct epigenetic changes that occur following the restoration of Ikaros binding to promoters of Ikaros-only and Ikaros-HDAC1 target genes were reproduced in cells derived from three different primary high-risk B-ALL following treatment with CK2 inhibitor CX-4945 (Figures 2c and d, Supplementary Figure S12). These results were also reproduced following treatment of high-risk primary B-ALL cells with a different CK2 inhibitor, TBB, (Supplementary Figures S13a and b compared with Figures 2a–d and Supplementary Figures S12 and S13c and d compared with Supplementary Figure 11).

In summary, our data reveal the mechanism by which chromatin remodeling and target gene expression are regulated by Ikaros alone and in complex with HDAC1 in B-ALL (Figure 2e). These data suggest that Ikaros can repress transcription of its target genes by inducing the formation of repressive chromatin via two distinct mechanisms: (1) direct Ikaros binding resulting in the formation of heterochromatin due to increased H3K9me³ and reduced H3K9ac; or (2) Ikaros recruitment of HDAC1, where the most prominent change is a strong increase in H3K27me³ along with reduced H3K9ac. In high-risk B-ALL, Ikaros ability to regulate chromatin remodeling of its target genes is impaired. In high-risk B-ALL with deletion of one Ikaros allele, inhibition of CK2 restores Ikaros-mediated epigenetic repression of the cell cycle-promoting genes. These data suggest that the ability to regulate chromatin remodeling is an essential part of Ikaros tumor-suppressor function. These studies provide new insight into the epigenetic regulation of gene expression in B-ALL and a rationale for the use of CK2 inhibitors as a novel treatment.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We would like to thank S Smale for critical reading of the manuscript. This work has been supported by National Institutes of Health (NIH) R01 HL095120, a St Baldrick's Foundation Career Development Award, a Hyundai Hope on Wheels Scholar Grant Award, the Four Diamonds Fund of the Pennsylvania State University, College of Medicine, and the John Wawrynovic Leukemia Research Scholar Endowment (to SD) a St Baldrick's Foundation Fellows Award and Hyundai Hope on Wheels Fellowship Grant Award (to CG). Additional funding for this work is from NSFC 81270613 (ZG), NIH R01GM109453 and 1UL1R033184 (to QL). This work was also supported by NIH R21CA162259, P20MD006988 a St Baldrick's Research Grant and a Hyundai Hope on Wheels Award (KJP).

AUTHOR CONTRIBUTIONS

CS performed the majority of the biological experiments, analyzed the data and participated in the manuscript preparation. XP provided bioinformatics and biostatistical analysis of the data and participated in the manuscript preparation. CG, YD, HL and ZG performed experiments. GY assisted in the data interpretation, participated in the experimental design and provided conceptual advice. MM provided vital reagents and conceptual advice. QL participated in the interpretation of biostatistical data. KJP provided vital reagents and conceptual advice and participated in the experimental design and in writing the manuscript. SD designed the experiments, interpreted the data and wrote the manuscript.

C Song^{1,8}, X Pan^{1,8}, Z Ge^{1,2}, C Gowda¹, Y Ding¹, H Li¹, Z Li^{1,3}, G Yochum⁴, M Muschen⁵, Q Li⁶, KJ Payne⁷ and S Dovat¹

¹Department of Pediatrics, Pennsylvania State University Medical College, Hershey, PA, USA;

²Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China;

³Jilin Province Animal Embryo Engineering Key Laboratory, College of Animal Science and Veterinary Medicine, Jilin University, Changchun, China;

⁴Department of Biochemistry and Molecular Biology, Pennsylvania State University Medical College, Hershey, PA, USA;

⁵University of California San Francisco, San Francisco, CA, USA;

⁶Department of Statistics, Pennsylvania State University, University Park, State College, PA, USA and

⁷Department of Pathology and Human Anatomy and Center for Health Disparities and Molecular Medicine, Loma Linda University, Loma Linda, CA, USA

E-mail: sdovat@hmc.psu.edu

⁸These authors contributed equally to this work

REFERENCES

- Lo K, Landau NR, Smale ST. LyF-1, a transcriptional regulator that interacts with a novel class of promoters for lymphocyte-specific genes. *Mol Cell Biol* 1991; **11**: 5229–5243.
- Georgopoulos K, Moore DD, Derfler B. Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment. *Science* 1992; **258**: 808–812.
- Georgopoulos K, Bigby M, Wang JH, Molnar A, Wu P, Winandy S *et al*. The Ikaros gene is required for the development of all lymphoid lineages. *Cell* 1994; **79**: 143–156.
- Winandy S, Wu P, Georgopoulos K. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. *Cell* 1995; **83**: 289–299.
- Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD *et al*. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature* 2007; **446**: 758–764.
- Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J *et al*. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. *Nature* 2008; **453**: 110–114.
- Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB *et al*. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. *N Engl J Med* 2009; **360**: 470–480.
- Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D *et al*. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature* 2012; **481**: 157–163.
- Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D *et al*. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. *J Clin Oncol* 2009; **27**: 5202–5207.
- Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B *et al*. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. *Leukemia* 2010; **24**: 1258–1264.
- Iacobucci I, Iraci N, Messina M, Lonetti A, Chiaretti S, Valli E *et al*. IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. *PLoS One* 2012; **7**: e40934.
- Kim J, Sif S, Jones B, Jackson A, Koipally J, Heller E *et al*. Ikaros DNA-binding proteins direct formation of chromatin remodeling complexes in lymphocytes. *Immunity* 1999; **10**: 345–355.
- Zhang J, Jackson AF, Naito T, Dose M, Seavitt J, Liu F *et al*. Harnessing of the nucleosome-remodeling-deacetylase complex controls lymphocyte development and prevents leukemogenesis. *Nat Immunol* 2012; **13**: 86–94.

- 14 O'Neill DW, Schoetz SS, Lopez RA, Castle M, Rabinowitz L, Shor E *et al.* An ikaros-containing chromatin-remodeling complex in adult-type erythroid cells. *Mol Cell Biol* 2000; **20**: 7572–7582.
- 15 Song C, Gowda C, Pan X, Ding Y, Tong Y, Tan BH *et al.* Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia. *Blood* 2015; **126**: 1813–1822.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

Supplementary Information accompanies this paper on the Leukemia website (<http://www.nature.com/leu>)

A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients

Leukemia (2016) **30**, 1440–1443; doi:10.1038/leu.2015.333

Several phenotypic, molecular and chromosomal markers of chronic lymphocytic leukemia (CLL) cells have been identified that are significantly associated with patient prognosis.^{1–6} However, these markers used singularly are inaccurate predictors of outcome for individual patients. Recent efforts have focused on combining markers to predict either treatment-free survival (TFS)^{4,7,8} or overall survival (OS),^{9–11} however, further effort is worthwhile to determine how to combine prognostic parameters, optimize risk stratification, simplify calculations and/or identify new prognostic variables.

Herein analyzing data from a cohort of Binet A patients, enrolled in a prospective multicenter observational study, we developed a weighted, multivariate score (progression-risk score (PRS)) integrating clinical, laboratory and biological parameters independently associated with TFS. The PRS was subsequently validated using an external cohort of CLL patients from the Mayo Clinic, Minnesota, USA.

We analyzed data from 480 newly diagnosed CLL patients enrolled in the O-CLL1-GISL protocol (clinicaltrials.gov identifier: NCT00917540). Of these, 337 cases with available biological (CD38, ZAP-70, *IGHV* mutational status and fluorescent *in situ* hybridization (FISH)) and clinical/laboratory parameters (sex, age, absolute lymphocyte count, Rai-modified stage, lactate dehydrogenase (normal range, 313–618 IU/l) and β 2-microglobulin level (normal range, 0.6–2.0 mg/l),¹¹ were included in this analysis (see Supplementary Methods).

Factors independently associated with TFS were included in the PRS. To account for differences in the magnitude of the association between individual independent factors and TFS, we assigned a weighted-risk score to each factor based on ranges of their corresponding hazard ratios (HR) (that is, 1 point for HR 1.1–1.9; 2 points for HR 2.0–2.9 and so on).⁹ The total risk score was then calculated by summing the ratings of each individual factor. Risk groups were identified combining risk categories with a non-statistically different TFS (see Supplementary Methods).

Baseline patient features of the training cohort are listed in Supplementary Table S1. Patients with Rai stage I and II were grouped for analysis according to convention.¹² Given the limited number of patients with del(11q23) and del(17p13), cytogenetic abnormalities identified by FISH were clustered in three risk groups (that is, low risk (del(13q14) and normal), intermediate risk (trisomy 12) and high risk (del(11q23) and del(17p13)). After a median 42 months follow-up (range, 6–82 months), 84/337 (24.9%) cases required treatment.

In multivariate analysis, Rai stage I–II, absolute lymphocyte count $\geq 10 \times 10^9/l$, elevated β 2-microglobulin levels, and *IGHV-UM* remained associated with shorter TFS (Table 1). The multivariate model was confirmed by bootstrap resampling (data not shown). Considering the HR of the independent factors, a risk score was assigned to each marker (Table 1); the total risk score was defined as the sum of the risk scores of the four individual parameters (range, 0–7). According to the predefined criteria (Supplementary Table S2), three different risk categories for TFS were determined: low (score 0–2), intermediate (score 3–5) and high risk (score 6–7; Supplementary Table S3).

Table 1. Univariate and multivariate Cox proportional Hazards Models for TFS

Variable	Univariate analysis		Multivariate analysis		
	HR (95% CI)	P-value	HR (95% CI)	P-value	Score
Age (years) < 60/≥ 60	1.12 (0.73–1.74)	0.59	–	–	–
Sex male/female	0.93 (0.6–1.44)	0.93	–	–	–
Rai stage 0/I–II	2.30 (1.47–3.50)	< 0.0001	1.76 (1.11–2.78)	0.015	0/1
ALC ($10^9/l$) < 10/≥ 10	3.43 (1.99–5.92)	< 0.0001	2.70 (1.54–4.72)	0.001	0/2
β 2-microglobulin normal/elevated	3.04 (1.96–4.70)	< 0.0001	2.65 (1.66–4.21)	< 0.0001	0/2
LDH normal/elevated	1.25 (0.57–2.71)	0.57	–	–	–
CD38 negative/positive	3.22 (2.06–5.02)	< 0.0001	1.40 (0.80–2.42)	0.24	–
ZAP-70 negative/positive	2.34 (1.51–3.61)	< 0.0001	1.0 (0.98–1.01)	0.72	–
<i>IGHV</i> mutated/unmutated	3.57 (2.32–5.50)	< 0.0001	2.39 (1.27–4.50)	0.007	0/2
FISH risk low+int/high	2.93 (1.46–5.90)	0.002	1.80 (0.84–3.88)	0.13	–

Abbreviations: ALC, absolute lymphocyte count; CI, confidence interval; HR, hazard ratio; LDH, lactate dehydrogenase.